Abbisko Pimicotinib NDA Progress Advances TGCT Therapy

Shanghai, China – April 22, 2026

In a major milestone for rare tumor therapeutics, Abbisko Therapeutics has announced significant regulatory progress for its investigational therapy pimicotinib (ABSK021), a highly selective CSF-1R inhibitor, reinforcing its potential as a first-in-class systemic treatment for tenosynovial giant cell tumor (TGCT). The advancement highlights Abbisko’s growing leadership in precision oncology and rare disease drug development, as global regulatory filings and clinical validation continue to gain momentum.

Regulatory Momentum Strengthens Pimicotinib Development

The company’s latest update underscores the acceptance of a New Drug Application (NDA) for pimicotinib by major regulatory authorities, including the U.S. FDA, marking a critical step toward potential commercialization in global markets. This follows earlier regulatory success, including approval in China by the National Medical Products Administration (NMPA), making pimicotinib the first systemic therapy approved for TGCT in that region.

The NDA submission is supported by robust clinical evidence from the Phase 3 MANEUVER trial, which demonstrated statistically significant improvements in objective response rate (ORR) compared with placebo, alongside meaningful benefits in pain reduction, joint mobility, and physical function. These outcomes reinforce pimicotinib’s potential as a best-in-class therapy addressing a major unmet need in TGCT treatment.

Additionally, the therapy has received Breakthrough Therapy Designation from regulatory agencies, enabling accelerated development pathways and priority review processes, further strengthening its global regulatory trajectory.

Clinical Efficacy and Patient-Centric Benefits

Clinical data from the Phase 3 program highlight pimicotinib’s ability to deliver deep and durable tumor responses, with response rates continuing to improve over time during extended follow-up. Patients treated with pimicotinib experienced significant reductions in tumor burden, as well as improvements in daily functioning and quality of life, key considerations in managing chronic and debilitating conditions like Tenosynovial Giant Cell Tumor.

TGCT is a rare, locally aggressive tumor affecting joints and surrounding tissues, often leading to pain, swelling, stiffness, and reduced mobility. In many cases, surgical intervention is the primary treatment option, but recurrence rates remain high, and repeated surgeries can significantly impact patient quality of life.

Pimicotinib’s oral, once-daily administration offers a non-invasive alternative to surgery, providing patients with a convenient and potentially long-term disease management solution. Its mechanism of action targets the CSF-1/CSF-1R signaling pathway, a key driver of tumor growth, enabling targeted modulation of disease biology rather than symptomatic treatment alone.

Strategic Partnerships and Global Commercial Outlook

Abbisko Therapeutics has entered into a global commercialization agreement with Merck KGaA, under which Merck is responsible for worldwide commercialization of pimicotinib. This collaboration enhances the therapy’s global reach and market potential, leveraging Merck’s established commercial infrastructure and expertise in oncology.

The partnership also supports ongoing regulatory submissions across multiple regions, including the United States and Europe, positioning pimicotinib for broad international adoption. With a strong pipeline focused on precision oncology and immuno-oncology, Abbisko continues to expand its portfolio of innovative therapies targeting high unmet medical needs.

As the pharmaceutical industry increasingly prioritizes targeted therapies and rare disease innovation, pimicotinib represents a transformational advancement in TGCT treatment, with the potential to redefine clinical standards and improve long-term patient outcomes.

This development marks a pivotal step in Abbisko’s evolution from a research-driven organization to a global oncology innovator, delivering next-generation therapies that address complex and underserved diseases.

Source: Abbisko Therapeutics press release